Title: A comparison of NAFLD and MAFLD diagnostic criteria in contemporary urban healthy
adults in China- a cross-sectional study
Version: 1 Date: 12 Sep 2022
Reviewer's report:
Comments to authors
Congratulations to authors
Manuscript is reasonably well written but need some language editing with a native speaker.
There are similar studies trying to characterize NAFLD/MAFLD subgroups, but this study
from an Asian country with different obesity cut off and definitions for metabolic syndrome is
pertinent.
Do you have any elastography reports to compare the subgroups? FIB-4 and NFS have
limitations as compared to image-based testing for fibrosis scores and amount of hepatic
steatosis?
Drug (herbal or dietary supplements) induced hepatic steatosis is a common occurrence in many
countries, did you consider this into your patient selection and analysis. It is sometimes difficult
to get this history from patients, particularly for OTC medications/products
I assume that most patients did not have biopsy, and this is not really required for diagnosis. But
did you consider liver biopsy in any of these patients, as in some cases the etiology of elevated
transaminases is speculative
I would recommend revising the discussion session and summarize it into 3 sections- first
briefly summarizing pertinent findings in this study and explaining its clinical relevance, second,
comparing it with existing literature and third session to explain the larger clinical relevance
and applicability of the study results with a mention of limitations of the study and scope of this
study to generate further studies
Title: A comparison of NAFLD and MAFLD diagnostic criteria in contemporary urban healthy
adults in China- a cross-sectional study
Version: 1 Date: 12 Sep 2022
Reviewer's report:
Comments to authors
Congratulations to authors
Manuscript is reasonably well written but need some language editing with a native speaker.
There are similar studies trying to characterize NAFLD/MAFLD subgroups, but this study
from an Asian country with different obesity cut off and definitions for metabolic syndrome is
pertinent.
Do you have any elastography reports to compare the subgroups? FIB-4 and NFS have
limitations as compared to image-based testing for fibrosis scores and amount of hepatic
steatosis?
Drug (herbal or dietary supplements) induced hepatic steatosis is a common occurrence in many
countries, did you consider this into your patient selection and analysis. It is sometimes difficult
to get this history from patients, particularly for OTC medications/products
I assume that most patients did not have biopsy, and this is not really required for diagnosis. But
did you consider liver biopsy in any of these patients, as in some cases the etiology of elevated
transaminases is speculative
I would recommend revising the discussion session and summarize it into 3 sections- first
briefly summarizing pertinent findings in this study and explaining its clinical relevance, second,
comparing it with existing literature and third session to explain the larger clinical relevance
and applicability of the study results with a mention of limitations of the study and scope of this
study to generate further studies
Please review this paper.
user
Title: A comparison of NAFLD and MAFLD diagnostic criteria in contemporary urban healthy
adults in China- a cross-sectional study
Version: 1 Date: 12 Sep 2022
Reviewer's report:
Comments to authors
Congratulations to authors
Manuscript is reasonably well written but need some language editing with a native speaker.
There are similar studies trying to characterize NAFLD/MAFLD subgroups, but this study
from an Asian country with different obesity cut off and definitions for metabolic syndrome is
pertinent.
Do you have any elastography reports to compare the subgroups? FIB-4 and NFS have
limitations as compared to image-based testing for fibrosis scores and amount of hepatic
steatosis?
Drug (herbal or dietary supplements) induced hepatic steatosis is a common occurrence in many
countries, did you consider this into your patient selection and analysis. It is sometimes difficult
to get this history from patients, particularly for OTC medications/products
I assume that most patients did not have biopsy, and this is not really required for diagnosis. But
did you consider liver biopsy in any of these patients, as in some cases the etiology of elevated
transaminases is speculative
I would recommend revising the discussion session and summarize it into 3 sections- first
briefly summarizing pertinent findings in this study and explaining its clinical relevance, second,
comparing it with existing literature and third session to explain the larger clinical relevance
and applicability of the study results with a mention of limitations of the study and scope of this
study to generate further studies
assistant